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Background: Alzheimer’s disease (AD) is the most common cause of dementia in older
patients. Rivastigmine (RV, Exelon, Novartis), a reversible cholinesterase inhibitor, improves
clinical manifestations of AD and may enhance ACh-modulated electroencephalogram
(EEG) alpha frequency.This pilot study aimed to determine the effects of two formulations
of RV [transdermal patch (RV-TDP) and oral capsules (TV-CP)] on alpha frequency, in
particular the posterior dominant rhythm, and cognitive function [assessed by the Mini-
Mental State Examination (MMSE)] in patients with AD.
Methods: Subjects with AD were assigned to receive either RV-TDP 10 cm2 or RV-CP
12 mg/day. All patients underwent EEG recordings at the beginning and end of the 18-
month study period using P3, P4, O1, and O2 electrodes, each at high (10.5–13.0 Hz) and
low (8.0–10.5 Hz) frequency. MMSE scores were determined at the start of the study (T0)
and at three successive 6-month intervals (T1, T2, andT3).
Results: RV-TDP administration (n = 10) maintained cognitive function as evidenced by
stable MMSE scores from baseline to 18 months (21.07 ± 2.4–21.2 ± 3.1) compared with
a decrease in MMSE score with RV-CP (n = 10) over 18 months [18.3 ± 3.6–13.6 ± 5.06
(adjusted for covariates p = 0.006)]. MMSE scores were signiﬁcantly different between
treatment groups from 6 months (p = 0.04). RV-TDP also increased the spectral power
of alpha waves in the posterior region measured with electrode P3 in a signiﬁcantly great
percentage of patients thanTV-CP from baseline to 18 months; 80% vs 30%, respectively
[p = 0.025 ( 2χ test)].
Conclusions: RV-TDP was associated with a greater proportion of patients with increased
posterior region alpha wave spectral power and signiﬁcantly higher cognitive function at
18 months, compared with RV-CP treatment. Our ﬁndings suggest that RV-TDP provides
an effective long-term management option in patients with AD compared with oral RV-CP.
This study is a pilot, open-label study with a clear explorative purpose and with a small
number of patients. Further randomized, double-blind, placebo-controlled trial studies with
a bigger sample size as well as healthy controls are needed to support these initial results.
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INTRODUCTION
In Alzheimer’s disease (AD), patients have reduced cerebral
production of choline acetyl transferase, leading to decreased
acetylcholine synthesis and impaired cortical cholinergic function
(Ferri et al., 2005; Ziabreva et al., 2006; World Health Organiza-
tion, 2011). Knowledge of this marked cholinergic deﬁcit led to
clinical research into the potential for therapeutically augment-
ing cholinergic activity (Perry et al., 1978; Caamano et al., 1994).
The ﬁrst agents to be investigated, acetylcholine precursors, were
found to be ineffective, and postsynaptic cholinergic receptor ago-
nists were found to have unacceptable side effects (Greenwald and
Davis, 1983; Holden and Kelly, 2002). Conversely, the results
of studies with acetyl cholinesterase inhibitors – agents which
increase cholinergic transmission by delaying the breakdown of
acetylcholine released into synaptic clefts – were encouraging
(Ashford et al., 1989). To date, the use of acetylcholinesterase
inhibitors is the only therapy to have shown consistently pos-
itive results in the management of AD (Holden and Kelly,
2002).
Large-scale multicenter trials have shown that rivastigmine
(RV), a “pseudo-irreversible” acetyl- and butyryl-cholinesterase
inhibitor with a phenylcarbamate structure, now approved for
use in 60 countries, is effective in improving patients’ cognitive,
behavioral, and daily functioning (Forette et al., 1999; McMillan,
1999; Rosler et al., 1999; Auriacombe et al., 2002; Burns et al., 2004;
Feldman and Lane, 2007).
Rivastigmine was the ﬁrst cholinesterase inhibitor to be
approved as a transdermal patch (TDP) for the treatment
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of mild-to-moderate AD (Winblad et al., 2007). Clinical data
support the RV-TDP pharmacokinetic proﬁle (Kurz et al., 2009),
demonstrating that smooth, continuous drug delivery trans-
lates into improved tolerability proﬁle compared with the oral
administration (Winblad et al., 2007; Lefevre et al., 2008). Trans-
dermal administration also provides additional beneﬁts includ-
ing improving adherence, increased convenience and ease of
use for caregivers, and a reduced impact on daily activi-
ties (Guay, 2008). Of note, a recent study has demonstrated
that the Clinical Global Impressions-Change scale (CGI-C),
evaluated by physicians, improved after the switch from
oral to transdermal RV, suggesting a better clinical efﬁcacy
(Reñé et al., 2014).
Patients with AD are known to have abnormal cortical sources
of resting-state EEG rhythms (Moretti et al., 2004). Studies also
show that resting-state EEG rhythms are sensitive to early stage
AD progression over a year (Moretti et al., 2004). Patients with
mild AD are characterized by a power decrease in posterior
alpha sources and a power increase in widespread delta sources
compared with normal elderly subjects (Moretti et al., 2004). In
patientswithmildAD,one-year follow-upEEG recordings showed
increased power of widespread delta sources and decreased power
of widespread alpha and posterior beta 1 sources. This suggests
that resting-state EEG sources are sensitive (at least at group level),
to the extent of cognitive decline that can occur in patients with
mild AD in 12 months (Babiloni et al., 2013). Resting-state EEG
could be a cost-effective and non-invasive marker for AD treat-
ment efﬁcacy in clinical studies (Moretti et al., 2004; Babiloni et al.,
2013).
The objectives of this single-center study in patients with AD
were to determine the effects of two formulations of RV (transder-
mal and oral) on cognitive decline – as assessed by Mini-Mental
State Examination (MMSE) scores. To support this effect on the
cognitive decline with a neurophysiological biomarker, the EEG
alpha frequency has been chosen, given the evidence indicating
that changes in acetylcholine cause alterations in alpha frequency,
in particular in the posterior cerebral regions alpha dominant
rhythm, as it is in theses regions that the dominant frequency
is most expressed (Babiloni et al., 2013).
MATERIALS AND METHODS
SUBJECTS
Subjects with AD were retrospectively recruited from the Trans-
lational Outpatient Memory Clinic (TOMC) of the Scientiﬁc
Institute for Research and Care (IRCCS) of Alzheimer’s and Psy-
chiatric Diseases “Centro S. Giovanni di Dio-Fatebenefratelli” in
Brescia, Italy. The previous diagnosis of ADwasmade according to
NINCDS-ADRDA criteria and the Diagnostic and Statistical Man-
ual ofMentalDisorders IV. Patients had been referred to theTOMC
already knowing they hadAD,but theywere not receiving any ther-
apy for AD prior to this study. Informed consent about the use
of data for research purposes was obtained from all participants
or their caregivers, according to the guideline of the local ethics
committee and Code of Ethics of the World Medical Association
(Declaration of Helsinki).
Patients were rated with a series of standardized diagnostic
and disease severity instruments, including the MMSE (Folstein
et al., 1975), the Clinical Dementia Rating Scale (CRD; Hughes
et al., 1982), theHachinski Ischemic Scale (HIS; Rosen et al., 1980),
and the Instrumental and Basic Activities of Daily Living (IADL,
BADL; Lawton and Brody, 1969). In addition, patients underwent
diagnostic neuroimaging procedures such as magnetic resonance
imaging (MRI), EEG, and laboratory testing to rule out other
causes of cognitive impairment. In addition, included patients
had no known problems with previous anticholinesterase therapy.
Patients with cognitive deﬁcits, due to psychological (anxi-
ety, depression, etc.) or physical [hypothyroidism, vitamin B12,
and folate deﬁciency, uncontrolled heart disease, uncontrolled
conditions (diabetes, etc.)] reasons were excluded.
This was not a study about safety or tolerability of the drug,
both already previously investigated in other clinical trials. This is
an explorative study that only wants to detect cognitive and neuro-
physiological differences in patients taking the two different forms
of RV. In this view, we prefer to choose retrospectively our patients
among themwhohave taken the higher doses in both formulations
for the 18-month follow-up period. In this retrospective analysis,
the higher number of patients for each group was collected. At the
end of the process, 10 patients for each group were recruited. As a
consequence, there was no exclusion from an initial larger number
of patients.
STUDY DESIGN
This was a single-center, clinical, explorative, non-randomized,
open-label, pilot study. Subjects were assigned to receive either
RV-TDP or RV capsules (RV-CP) according to patient preference
or availability. Patients with RV-CP were titrated to the maximum
dosage in 4-week steps over 16 weeks. In other words, those in the
RV-CP group were up-titrated from 3 mg/day (1 and 5 mg, twice
a day) in steps of 3 mg/day to a maximum of 12 mg/day (6 mg,
twice a day).
Patients in the RV-TDP group were up-titrated from a 5 cm2
(4.5 mg/die) starting dose to a maximum size of 10 cm2 patch
(9.5 mg/die) after 8 weeks. Patients were administered at the
highest dose for the entire duration of the study.
The patch was applied to RV-TDP patients by caregivers to
clean, dry, hairless skin on the patient’s upper back every morn-
ing and worn for 24 h, during which normal activities including
bathing were allowed. To minimize possible skin irritation, patch
placement on the upper back was alternated between the left and
right sides, daily. RV-CP patients took a capsule with breakfast and
one with their evening meal.
Given the explorative nature of the study, a power analysis was
not performed to determine the study sample size.
To allow comparisons between the two groups (oral and
TDP), the following EEG measurements were carried out: (1)
high alpha and low alpha frequency power at each electrode
separately; (2) with total high and low alpha frequency power
at each electrode; (3) high alpha frequency power estimated
as the sum at all four electrodes; (4) low alpha frequency
power estimated as the sum at all four electrodes low; (5)
total high and low alpha frequency power estimated as the sum
of all four electrodes. MMSE scores were determined at the
start of the study and at three successive 6-month intervals
(T0, T1, T2, and T3).
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EEG RECORDINGS
All patients underwent EEG recordings at the beginning and at
the end of the 18-month study period using P3, P4, O1, and
O2 electrodes each at high (10.5–13.0 Hz) and low (8.0–10.5 Hz)
frequency. These electrodes were chosen as the detection in alpha
frequency changes is better performed on posterior brain areas. All
EEG recordings were obtained in the morning with subjects rest-
ing comfortably with eyes closed. The EEG activity was recorded
continuously for 5 min from 19 sites by using electrodes set in
an elastic cap (Electro-Cap International, Inc.) and positioned
according to the 10–20 international systems (Fp1, Fp2, F7, F3,
Fz, F4, F8, T3, C3, Cz, C4, T4, T5, P3, Pz, P4, T6, O1, and O2).
The ground electrode was placed in front of Fz. The left and right
mastoids served as the reference for all electrodes.
Data were recorded with a 0.3–70 Hz band-pass ﬁlter and
digitized at a 250 Hz sampling rate (BrainAmp, BrainProducts,
Germany). Electrode skin impedance was set at <5 kHz. Verti-
cal and horizontal eye movements were detected by recording the
electro-oculogram (EOG). In order to keep a constant level of
vigilance, an operator controlled the subject and the EEG traces,
alerting the subject when there were signs of behavioral and/or
EEG drowsiness.
The recording time of 5 min was considered optimal because,
although longer recordings would have reduced data variability,
they would also have increased the possibility of slowing of EEG
oscillations due to reduced vigilance and arousal.
Off-line recordings were used to calibrate the scalp record-
ings to the common average prior to EEG artifact detection and
analysis.
ANALYSIS OF INDIVIDUAL FREQUENCY BANDS
EEG data were analyzed and fragmented off-line in consecutive
2-s epochs. A digital Fast Fourier Transform (FFT)-based power
spectrum analysis (Welch technique, Hanning windowing func-
tion, no phase shift) computed the power density of EEG rhythms
with a 0.5 Hz frequency resolution (range: 2–45 Hz). Two alpha
frequencies – lowalpha (8–10.5Hz) andhigh alpha (10.5–13 Hz) –
were selected according to the literature guidelines (Klimesch,
1997, 1999; Moretti et al., 2004, 2007a,b, 2008, 2009a,b).
An average of 140 epochs (range: 130–150) was analyzed. EEG
epochs with artifacts underwent preliminary identiﬁcation by an
automatic computerized procedure (Moretti et al., 2003, 2004,
2007a,b, 2008, 2009a,b, 2011a,b), then automatic selections were
double-checked and conﬁrmed manually by two expert electro-
encephalographists and epochs with muscular, ocular and other
types of artifacts were discarded.
STATISTICAL ANALYSIS
The Wilcoxon signed-rank test was performed to compare EEG
spectral power measurements taken at T0 and T18. The Wilcoxon
test is a non-parametric alternative to the paired Student’s t-test for
related samples. The Chi-square test was used to identify statistical
difference in non-continuous data.
A multivariate ANCOVA model was used to evaluate the effect
of the MMSE baseline score on each difference between T0 and
T18. To have a control analysis for the ﬁnal result, difference
between the MMSE score at T0 and T18 was evaluated also with
an uncovaried analysis. The p-value was set to <0.05. For all
analyses, the IBM SPSS Statistics for Windows, Version 20.0, was
used.
RESULTS
PATIENT DISPOSITION AND BASELINE DEMOGRAPHICS AND CLINICAL
CHARACTERISTICS
Twenty patients were enrolled in the study. Ten patients each were
assigned to the RV-TDP and RV-CP groups. There were no signif-
icant differences in age, duration of education, or MMSE score at
baseline between the two groups (Table 1).
MMSE DATA
Mini-Mental State Examination scores decreased in patients tak-
ing the oral formulation while remaining unchanged over the
18-month study period in those taking RV-TDP; at 6, 12, and
18 months, MMSE scores were signiﬁcantly higher in patients
taking RV-TDP than RV-CP (p = 0.04, 0.006, 0.001 at T1, T2,
and T3, respectively; Figure 1), The one-way ANOVA showed
the differences in MMSE scores at 18 months between patients
in the RV-TDP and RV-CP groups were statistically signiﬁcant
(p = 0.023). Moreover, using a multivariate ANCOVA model
with baseline MMSE score as a covariate, the differences between
MMSE scores from baseline to 12 and 18 months were signiﬁ-
cantly greater in patients taking RV-TDP compared with those
taking RV-CP (p = 0.042 and p = 0.006, for baseline to 12 months
and baseline to 18 months, respectively; Figure 2).
EEG DATA
RV-TDPandRV-CP increased spectral power (high and lowalpha)
in the posterior region over 18 months as measured by the sum of
all the electrodes ( electrodes) in 8 and 4 patients, respectively,
with the proportion of patients with increased spectral power at
18 months vs baseline being higher for RV-TDP than RV-CP (80
vs 40%; p = 0.068; Table 2). Applying the χ2 test, this difference
reaches statistically signiﬁcance for spectral power measured with
electrode P3 (80 vs 30%; OR: 0.107; p = 0.025; Table 2, Figure 3).
DISCUSSION
In this study, we compared the cognitive and neurophysiological
outcomes of two groups of patients, both receiving RV, but in
Table 1 | Socio-demographic and cognitive characteristics at baseline.
RV-TDP RV-CP p-Value
N (male/female) 10 (4/6) 10 (4/6)
Age (years) 82.2 ± 2.3 80.3 ± 2.5 0.2
Education (years) 5.4 ± 1.7 4.9 ± 2.1 0.1
MMSE 21.07 ± 2.4 18.3 ± 3.6 0.08
Disease duration (months) 38.2 ± 1.8 39.5 ± 0.8 0.2
IADL 5 lost/8 5 lost/8
RV-CP, Rivastigmine capsules; RV-TDP, Rivastigmine transdermal patch; MMSE,
Mini-Mental State Examination; IADL, instrumental activities of daily living; (mean
value ± standard deviations).
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FIGURE 1 | Mean of the Mini-Mental State Examination (MMSE) score
at baseline andT6,T12, andT18 follow-up in each of the two groups
(RV-TDP, rivastigmine transdermal patch; RV-CP, rivastgmine
capsules).
FIGURE 2 | Mean of the MMSE score difference between follow-up at
T18,T12,T6, and baseline in each group with MMSE baseline score
covariation (RV-TDP, rivastigmine transdermal patch; RV-CP,
rivastgmine capsules).
Table 2 |Wilcoxon signed-rank test results for EEG power spectra
analysis.
LOW + HIGHALPHA FREQUENCY POWER SPECTRA (8.0–13.0 Hz)
Electrode RV T18 > baseline Odds ratio (95% CI) χ2 test p-value
P3 TDP 8 (80.0%) 0.107 (0.014–0.838) 0.025
CP 3 (30.0%)
P4 TDP 7 (70.0%) 0.429 (0.068–2.684) 0.361
CP 5 (50.0%)
O1 TDP 7 (70.0%) 0.429 (0.068–2.684) 0.361
CP 5 (50.0%)
O2 TDP 7 (70.0%) 0.643 (0.101–4.097) 361
CP 6 (60.0%)
 electrodes TDP 8 (80.0%) 0.167 (0.023–1.232) 0.068
CP 4 (40.0%)
RV-CP, Rivastigmine capsules; RV-TDP, Rivastigmine transdermal patch; T0,
baseline visit; T18, 18-month visit; , sum.
FIGURE 3 | Percentage of patients with increased alpha power atT18
follow-up as compared to the baseline measured at the P3 electrode
(RV-TDP, rivastigmine transdermal patch; RV-CP, rivastgmine capsules).
two different formulations – capsules andT DP. All patients were
titrated to the maximum dosage, i.e., 12 mg/day for capsules and
9.5 mg/24 h for the TDP. Cognitive performance was evaluated by
MMSE score, whereas neurophysiological outcomes were detected
by means of alpha frequency EEG power spectra computation in
the posterior regions of the brain.
Our results show that administration of RV-TDP is associ-
ated with a substantial maintenance of cognitive function as
evidenced by lack of signiﬁcant changes in MMSE scores in
the time. Of note, MMSE scores, as well as age and educa-
tion were not signiﬁcantly different between the two treatment
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groups at baseline. Lack of cognitive impairment, evaluated
by MMSE score, was evident in each of the three follow-up
points (at 6, 12, and 18 months of observation) only in patients
receiving RV-TDP. Moreover, the difference in the MMSE score
between treatment groups was signiﬁcantly different at 12 and
18 months, but not at 6 months. These results suggest that the
TDP formulation stabilizes cognitive performance compared with
the capsule formulation, with a signiﬁcant difference seen at
medium-term treatment duration, and remaining constant there-
after. Conversely, in patients taking RV-CP, there is a progressive
deterioration of cognitive performance, together with a progres-
sively greater difference compared with MMSE score in RV-TDP
recipients. Our results conﬁrm and extend previous studies show-
ing the potential therapeutic advantage of TV-TDP vs RV-CP
treatment (Winblad et al., 2007; Riedel et al., 2012). The trans-
dermal formulation of RV is a prolonged-release drug, which
avoids ﬂuctuations in blood concentrations of RV. As a theoretical
hypothesis, the constant stimulation of cholinergic receptors could
have long-lasting beneﬁcial effects on cognition over time. More-
over, maintenance of cognitive function over time could suggest a
neuroprotective effect on the cholinergic system itself, preventing
massive degeneration. Further studies are required to conﬁrm this
hypothesis.
It should be possible that the results have been biased by the
different characteristic of the groups, with one group experiencing
a more rapid decline. Even if the MMSE at baseline was lower in
RV-CP group, although not signiﬁcantly, it should be remarked
that the composition of the groups was not based on any clinical
feature, but it was completely random. Consequently, it would
be more logical to think that patients with different characteris-
tics are mixed between the two groups. In contrast, the results
were positive and constant over time only in the group taking RV
transdermal. Anyway, the present methodology is not suitable to
address this limitation.
Regarding neurophysiological measures, our results show a
major increase in the spectral alpha frequencypower (both lowand
high alpha) in the posterior region in patients taking RV-TDP after
18 months of treatment. Previous studies have demonstrated the
reliability of a pharmaco-EEG approach in evaluating both drug
response and cognitive performance. Analysis of EEG-recorded
electrical power (the brain ﬁeld potential) is a very sensitive tool
for characterization of the effects of drugs on the central nervous
system (Dimpfel and Decker, 1984). Since this EEG-based method
was ﬁrst used, it has become increasingly clear that, depending on
the particular behavioral condition or drug, the electrical power of
single frequency ranges (as deﬁned in Dimpfel et al., 1987) change
independently from each other (Dimpfel et al., 1988).
The pattern of brain ﬁeld potential changes with respect to
specially deﬁned frequency ranges with a speciﬁc disease or fol-
lowing drug application is called an“electrical activity ﬁngerprint”
(Dimpfel, 2003). Thismethod has been used to obtain ﬁngerprints
of more than 100 compounds, including >50 standard drugs
(e.g., neuroleptics, tranquilizers, analgesics, stimulants, antide-
pressants, narcotics, and sedatives). Interestingly, in general, these
ﬁngerprints are similar for drugs with similar indications and
markedly different for drugs with different indications (Dimpfel,
2003, 2005).
A large body of literature has demonstrated that choliner-
gic neuromodulation augments the top–down impact of spatial
attention on oscillations in the human visual cortex, specif-
ically in the EEG alpha frequency band. Other studies have
also shown that cholinergic agonists enhance the hemodynamic
blood oxygenation level dependent (BOLD) response (Furey
et al., 2000; Bentley et al., 2003) to attention to stimuli in visual
cortex or spike-rates recorded invasively in the primary visual
cortex (Herrero et al., 2008), but the studies did not examine
oscillatory phenomena. Furthermore, the cholinergic impact on
alpha frequency-related spatial attention effects correlated with
drug-induced performance improvement (Bauer et al., 2012).
This relationship indicates that the cholinergic impact on cog-
nitive alpha frequency-related effects is not merely a secondary
phenomenon.
The alpha frequency rhythm is mainly modulated by the
thalamic and subcortical structure, mostly in the resting state
(Steriade, 2006). An intriguing possible explanation of our results,
to be veriﬁed, is that the power increase of alpha spectral power
in the brain could be tuned by the peculiar modulation of
butyrylcholinesterase on thalamic nuclei. The restoration of the
cholinergic system in a partly physiological way, without strong
peak ﬂuctuations of drug concentrations, could prevent the synap-
tic loss typically seen in AD. In turn, the improved functioning
of the cholinergic system is based both on the increase in alpha
frequency power and the improvement of cognitive performance
(Moretti et al., 2012a,b).
A range of studies have reported a strong relationship between
EEG alpha activity and memory performance or intelligence,
suggesting that the relationship between the dynamics of alpha
frequency and cognitive performance is not correlative but causal
in nature (Klimesch, 1997; Niedermeyer, 1997; Jausovec and
Jausovec,2000; Neubauer et al., 2002; Stipacek et al., 2003; Grabner
et al., 2004; Doppelmayr et al., 2005b). A recent study has demon-
strated that the induction of large alpha power by neuro-feedback
training or repetitive transcranial magnetic stimulation (rTMS)
using the alpha frequency range, exactly mimicked the typical sit-
uation for good memory performance under normal situations,
thus enhancing cognitive performance (Klimesch et al., 2003). In
particular, the increase in EEG alpha activity has been correlated
with better retrieval of information stored in the semantic long-
term memory. Moreover, in a different study, verbal-semantic
and spatial-semantic performances were both associated with two
different intelligence tests. The results showed that more intelli-
gent subjects showed signiﬁcantly larger alpha activity in the left
hemisphere (at centro-parietal regions) compared with less intel-
ligent subjects (Doppelmayr et al., 2005a). Our results conﬁrm
these previous studies, showing an increase in alpha power in sub-
jects without cognitive impairment. Of note, the increase in alpha
power was more evident in the left hemisphere.
An important observation is that our results show an asso-
ciation between the minor cognitive decline in patients taking
transdermal RV and the increase in alpha frequency. This conﬁrms
previous ﬁndings that cognitive performances are best correlated
with increased power in the alpha frequency. It is to remark that
studieswith bigger sample sizewill allowunambiguous correlation
analysis.
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Although not the focus of this study, these results add further
weight to the existing evidence from our group on the possi-
ble diagnostic and prognostic role of EEG markers in patients
with prodromal and diagnosed AD, an area that warrants further
study.
A possible bias of the study is that changes in alpha frequency
could be due to the natural course of AD. Most of the available
literature shows that AD causes a decrease in alpha frequency.
Our results show that this happens only in people taking RV cap-
sules, while in patients taking RV transdermal an increase of the
alpha frequency power occurs. Anyway, further studies with larger
sample size and control groups are needed to conduct powerful
correlation analysis.
STUDY LIMITATIONS
This study is a pilot, open-label study with a clear explorative
purpose and with a small number of patients, providing only pre-
liminary evidence. As a consequence, it leaves the manuscript
open to conjecture. However, it is an explorative study which
opens future scientiﬁc pathways and debate that may be con-
ﬁrmed or not. It is clear that further randomized, double-blind,
placebo-controlled trial studies with a bigger sample size as well as
healthy controls are needed to support these initial observations
and claims. The favorable outcomes observed in this study may be
a useful practical guideline to help clinicians and neurologists to
decide a treatment in AD.
CONCLUSIONS
As a conclusion, ﬁndings from this study suggest that 18-month
treatment with RV TDP was associated with a signiﬁcantly greater
proportion of patients with increased posterior region alpha wave
spectral power measured using the P3 electrode, and signiﬁ-
cantly higher cognitive function as assessed using the MMSE scale,
compared with oral RV.
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